Immunome Inc. (IMNM) stock
Close on Nov 11, 2026Market cap $2.17BP/E –Yield –
Immunome Inc. saw revenue fall 63.3% to $4.02M over the twelve months to Mar 31, 2026. Free cash flow was -$205.52M. At the latest close the market valued the company at $2.17B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.17B
- P/E ratio
- –
- Price to sales
- 539.46
- Price to book
- 4.77
- Dividend yield
- –
- Free cash flow yield
- -9.49%
Fundamentals
- Revenue
- $4.02M
- Net income
- -$224.59M
- EPS, diluted
- -$2.37
- Free cash flow
- -$205.52M
Trading
- Next earnings
- Mar 2, 2027 (estimated, after the close)
- Previous close
- $18.65
- Open
- $18.81
- Day's range
- $18.70 – $19.29
- Volume
- 873,282
- Average volume (20 days)
- 1,532,943
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.75
- 52-week range
- $16.11 – $30.06
- RSI (14 days)
- 48.5
- Volatility (1 year)
- 61.1%
- Relative volume
- 0.67×
- WACC
- 13.6%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMNM | S&P 500 | Difference | IMNM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.5% | -2.4% | −0.0 pts | ||
| 3 months | -27.4% | -1.2% | −26.2 pts | ||
| Year to date | -11.2% | +12.3% | −23.5 pts | ||
| 1 year | +8.8% | +12.4% | −3.6 pts | ||
| 3 years | +135.7% | +78.8% | +56.9 pts | +33.1% | +21.4% |
| 5 years | +4.4% | +75.2% | −70.7 pts | +0.9% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immunome filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Immunome
Pharmaceutical Preparations
Immunome is a clinical-stage biotechnology company focused on discovering, designing, and developing targeted oncology therapeutics. Its pipeline centers on antibody-drug conjugates (ADCs), gamma secretase inhibitors, and radioligand therapies designed to treat solid tumors and hematologic malignancies. Primary investigational programs include varegacestat for desmoid tumors, IM-1021 for ROR1-expressing cancers such as B-cell lymphomas, and IM-3050 for fibroblast activation protein-positive solid tumors. In addition, the firm is advancing preclinical ADC candidates supported by its proprietary HC74 topoisomerase 1 inhibitor payload and linker technologies. The company's end users and customers encompass cancer patients, healthcare providers, and clinical trial participants seeking targeted oncologic treatments.
Company profile, executives and historyImmunome stock: common questions
What is Immunome's stock price?
IMNM closed at $19.07 on Nov 11, 2026, up 2.25% on the day. Over the past 52 weeks it traded between $16.11 and $30.06.
What is Immunome's market cap?
Immunome was worth $2.17B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IMNM's P/E ratio?
Immunome lost money over the twelve months to Mar 31, 2026 (diluted EPS -$2.37), so it has no meaningful P/E ratio.
How much revenue does Immunome make?
Immunome reported revenue of $4.02M for the twelve months to Mar 31, 2026, down 63.3% from a year earlier.
Does Immunome pay a dividend?
No. Immunome has not paid a cash dividend over the last twelve months.
When does Immunome report earnings next?
Immunome is expected to report Q4 FY2026 results on Mar 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has IMNM stock performed over the past year?
Including dividends, IMNM returned +8.8% over the past year, against +12.4% for the S&P 500.
How many IMNM shares are sold short?
16M shares were sold short at the latest FINRA report, 15.22% of the float, or 12.8 days of average trading volume.
Who are Immunome's competitors?
Companies most similar to Immunome by business, industry and size include BOLT, MRKR, CBIO, ADAG, APLM.
See a number that looks wrong?